Apollomics given 180-day extension to meet minimum bid price requirement, positive.

From GlobeNewswire: 2024-07-16 16:47:00

Apollomics Inc. (Nasdaq: APLM) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share for its Ordinary Shares, granting time until January 13, 2025. Failure to meet this requirement may result in delisting from the Nasdaq Capital Market. Apollomics is actively monitoring its share prices and exploring options to regain compliance. The company’s lead programs include vebreltinib (APL-101) and uproleselan (APL-106), targeting non-small cell lung cancer and hematologic cancers. For more information, visit www.apollomicsinc.com.

The extension granted by Nasdaq highlights the company’s commitment to addressing difficult-to-treat cancers through innovative therapies that harness the immune system and target specific molecular pathways. Compliance with Nasdaq listing requirements is essential for maintaining the company’s continued growth and development of oncology drug candidates. With ongoing clinical trials in the United States and China, Apollomics remains focused on achieving positive outcomes for patients with various types of cancer.



Read more at GlobeNewswire: Apollomics Granted 180-Day Extension to Regain Compliance